Page last updated: 2024-12-11

ceftizoxime

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6533629
CHEMBL ID528
CHEBI ID553473
SCHEMBL ID37504
MeSH IDM0023550

Synonyms (47)

Synonym
(6r,7r)-7-({(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
D07658
ceftizoxime (inn)
ceftix
fr-13479
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6r,7r)-
(6r,7r)-7-[[(2z)-2-(2-imino-3h-thiazol-4-yl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C06890
DB01332
syn-7-(2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
(6r,7r)-7-(2-(2-amino-4-thiazolyl)-2z-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure
ceftizoximum [inn-latin]
ceftizoxime [inn:ban]
(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxyamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-carbonsaeure-7-(z)-(o-methyloxim)
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4- thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6r-(6-alpha,7-beta(z)))-
ceftizoxima [inn-spanish]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6r-(6alpha,7beta(z)))-
CHEMBL528
ceftizoxima
7beta-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2,3-didehydropenam-2-carboxylic acid
CHEBI:553473 ,
ceftizoximum
(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[[(2z)-2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[[(2z)-2-(2-azanyl-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
A836131
(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
c43c467dpe ,
unii-c43c467dpe
C2622
S4812
AKOS025310621
ceftizoxime [inn]
ceftizoxime [vandf]
(6r,7r)-7-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
ceftizoxime [usp-rs]
ceftizoxime [who-dd]
ceftizoxime [mi]
ceftizoxime [jan]
SCHEMBL37504
HY-B1596
CS-0013519
DTXSID5022772
(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
bdbm237182
CCG-268439
EN300-21584677

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" These top candidates were then evaluated for their activity in vivo, and their pharmacokinetic behavior in various animal models was explored."( Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
Counter, FT; Draheim, SE; Eudaly, JA; Kasher, JS; Pike, AJ; Ternansky, RJ, 1993
)
0.29
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" Although the participation of the particular transporters in observed drug-drug interactions can be difficult to confirm in humans, this review focuses mainly on pharmacokinetic interactions of clinically important drugs."( Transporter-mediated Drug Interactions.
Tsuji, A, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" For this reason, the dosage of [corrected] these drugs should be carefully evaluated [corrected] to minimize side effects."( Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study.
Aktas, M; Cankaya, M; Coban, TA; Gül, İ; Kuzucu, M, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutathione reductase, mitochondrialHomo sapiens (human)Ki22.76000.80003.45006.1000AID1803292
Carbonic anhydrase 1Homo sapiens (human)Ki68.95000.00001.372610.0000AID1803130
Carbonic anhydrase 2Homo sapiens (human)Ki68.95000.00000.72369.9200AID1803130
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Multidrug resistance-associated protein 4Homo sapiens (human)Km18.00001.90004.27259.6900AID1219900
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (77)

Processvia Protein(s)Taxonomy
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cellular oxidant detoxificationGlutathione reductase, mitochondrialHomo sapiens (human)
cellular response to oxidative stressGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione metabolic processGlutathione reductase, mitochondrialHomo sapiens (human)
cell redox homeostasisGlutathione reductase, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
temperature homeostasisGlutathione peroxidase 1Homo sapiens (human)
endothelial cell developmentGlutathione peroxidase 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGlutathione peroxidase 1Homo sapiens (human)
triglyceride metabolic processGlutathione peroxidase 1Homo sapiens (human)
glutathione metabolic processGlutathione peroxidase 1Homo sapiens (human)
sensory perception of soundGlutathione peroxidase 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressGlutathione peroxidase 1Homo sapiens (human)
response to xenobiotic stimulusGlutathione peroxidase 1Homo sapiens (human)
response to symbiotic bacteriumGlutathione peroxidase 1Homo sapiens (human)
UV protectionGlutathione peroxidase 1Homo sapiens (human)
response to hormoneGlutathione peroxidase 1Homo sapiens (human)
response to selenium ionGlutathione peroxidase 1Homo sapiens (human)
response to gamma radiationGlutathione peroxidase 1Homo sapiens (human)
arachidonic acid metabolic processGlutathione peroxidase 1Homo sapiens (human)
lipoxygenase pathwayGlutathione peroxidase 1Homo sapiens (human)
response to estradiolGlutathione peroxidase 1Homo sapiens (human)
response to hydroperoxideGlutathione peroxidase 1Homo sapiens (human)
response to vitamin EGlutathione peroxidase 1Homo sapiens (human)
regulation of mammary gland epithelial cell proliferationGlutathione peroxidase 1Homo sapiens (human)
cellular response to oxidative stressGlutathione peroxidase 1Homo sapiens (human)
response to nicotineGlutathione peroxidase 1Homo sapiens (human)
epigenetic regulation of gene expressionGlutathione peroxidase 1Homo sapiens (human)
vasodilationGlutathione peroxidase 1Homo sapiens (human)
response to hydrogen peroxideGlutathione peroxidase 1Homo sapiens (human)
hydrogen peroxide catabolic processGlutathione peroxidase 1Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGlutathione peroxidase 1Homo sapiens (human)
skeletal muscle tissue regenerationGlutathione peroxidase 1Homo sapiens (human)
blood vessel endothelial cell migrationGlutathione peroxidase 1Homo sapiens (human)
fat cell differentiationGlutathione peroxidase 1Homo sapiens (human)
myoblast differentiationGlutathione peroxidase 1Homo sapiens (human)
cell redox homeostasisGlutathione peroxidase 1Homo sapiens (human)
fibroblast proliferationGlutathione peroxidase 1Homo sapiens (human)
skeletal muscle fiber developmentGlutathione peroxidase 1Homo sapiens (human)
neuron apoptotic processGlutathione peroxidase 1Homo sapiens (human)
myoblast proliferationGlutathione peroxidase 1Homo sapiens (human)
response to folic acidGlutathione peroxidase 1Homo sapiens (human)
biological process involved in interaction with symbiontGlutathione peroxidase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionGlutathione peroxidase 1Homo sapiens (human)
heart contractionGlutathione peroxidase 1Homo sapiens (human)
angiogenesis involved in wound healingGlutathione peroxidase 1Homo sapiens (human)
regulation of proteasomal protein catabolic processGlutathione peroxidase 1Homo sapiens (human)
cellular response to glucose stimulusGlutathione peroxidase 1Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaGlutathione peroxidase 1Homo sapiens (human)
cellular oxidant detoxificationGlutathione peroxidase 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlutathione peroxidase 1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayGlutathione peroxidase 1Homo sapiens (human)
positive regulation of supramolecular fiber organizationGlutathione peroxidase 1Homo sapiens (human)
glutathione transportMicrosomal glutathione S-transferase 1Homo sapiens (human)
cellular response to lipid hydroperoxideMicrosomal glutathione S-transferase 1Homo sapiens (human)
cellular oxidant detoxificationMicrosomal glutathione S-transferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
electron transfer activityGlutathione reductase, mitochondrialHomo sapiens (human)
NADP bindingGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione-disulfide reductase (NADPH) activityGlutathione reductase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingGlutathione reductase, mitochondrialHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
glutathione peroxidase activityGlutathione peroxidase 1Homo sapiens (human)
protein bindingGlutathione peroxidase 1Homo sapiens (human)
SH3 domain bindingGlutathione peroxidase 1Homo sapiens (human)
phospholipid-hydroperoxide glutathione peroxidase activityGlutathione peroxidase 1Homo sapiens (human)
glutathione transferase activityMicrosomal glutathione S-transferase 1Homo sapiens (human)
glutathione peroxidase activityMicrosomal glutathione S-transferase 1Homo sapiens (human)
protein bindingMicrosomal glutathione S-transferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
mitochondrial matrixGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
external side of plasma membraneGlutathione reductase, mitochondrialHomo sapiens (human)
extracellular exosomeGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
mitochondrionGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
Lewy bodyGlutathione peroxidase 1Homo sapiens (human)
cytoplasmGlutathione peroxidase 1Homo sapiens (human)
mitochondrionGlutathione peroxidase 1Homo sapiens (human)
mitochondrial matrixGlutathione peroxidase 1Homo sapiens (human)
cytosolGlutathione peroxidase 1Homo sapiens (human)
mitochondrionGlutathione peroxidase 1Homo sapiens (human)
cytosolGlutathione peroxidase 1Homo sapiens (human)
mitochondrionMicrosomal glutathione S-transferase 1Homo sapiens (human)
mitochondrial outer membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
peroxisomal membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
endoplasmic reticulumMicrosomal glutathione S-transferase 1Homo sapiens (human)
endoplasmic reticulum membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
plasma membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
azurophil granule membraneMicrosomal glutathione S-transferase 1Homo sapiens (human)
mitochondrionMicrosomal glutathione S-transferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (184)

Assay IDTitleYearJournalArticle
AID416659Antimicrobial activity against Bacteroides fragilis ATCC 237452007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID548475Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID543952Antibacterial activity against tetracycline-resistant Staphylococcus aureus COL-S carrying SAmecA plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID584301Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus sciuri subsp. carnaticus ATCC 700058T by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID528533Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B502 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID584291Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP01(CCUG 43834T) by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID543953Antibacterial activity against tetracycline-resistant Staphylococcus aureus COL-S carrying SSpbpD plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID416821Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as bacterial killing at 6 mg/kg/day administered every 2 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID584296Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP06 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID416662Half life in Bacteroides fragilis ATCC 23745 and Enterobacter cloacae isolate 22491-infected BALB/c mouse mixed infection abscesses model at 100 mg/kg administered as 36 doses every 2 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID584303Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus sciuri subsp. rodentium ATCC 700061T by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID584305Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP02 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID164562In vitro minimum inhibitory concentration (MIC) against NCTC 10490 strain of Pseudomonas aeruginosa1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antibacterial activity of new 1-oxa-1-dethiacephalosporins.
AID548472Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID548473Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID416837Antimicrobial activity against Enterobacter cloacae isolate 22491 assessed as mutation prevention concentration2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID548255Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID162738In vitro minimum inhibitory concentration (MIC) against Proteus mirabilis 11980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antibacterial activity of new 1-oxa-1-dethiacephalosporins.
AID95890In vitro inhibitory activity against Klebsiella X261990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID163047In vitro inhibitory activity against Proteus rettgeri C241990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID162760In vitro inhibitory activity against Pseudomonas aeruginosa X2581990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID584304Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP01 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID528741Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC BAA-611 harboring PBP-2X V405A mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548253Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID528527Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B8 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID416823Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as bacterial killing at 24 mg/kg/day administered every 4 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID584295Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP05 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID416835Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as increase in resistant bacterial count per abscess at 96 mg/kg/day administ2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID584302Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus sciuri subsp. sciuri ATCC 29062T by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID681152TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:4
Transporter-mediated Drug Interactions.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID528534Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B503 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID528532Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B68 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID416660Antimicrobial activity against Enterobacter cloacae isolate 224912007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID416834Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as increase in resistant bacterial count per abscess at 24 mg/kg/day administ2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID95888In vitro minimum inhibitory concentration (MIC) against Klebsiella pneumonia 121980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antibacterial activity of new 1-oxa-1-dethiacephalosporins.
AID207057In vitro inhibitory activity against Staphylococcus aureus X1.11990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID528526Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B7 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID584300Antibacterial activity against mecA-negative Staphylococcus fleurettii SFMN02 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID416822Antimicrobial activity against Bacteroides fragilis ATCC 23745 infected BALB/c mouse mixed infection abscesses model co-infected with Enterobacter cloacae isolate 22491 assessed as bacterial killing at 24 mg/kg/day administered every 4 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID548474Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID85799In vitro inhibitory activity against Haemophilus influenza C.L1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID19542Plasma half-life in human after intravenous administration1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID416829Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as reduction in bacterial load per abscess at 1536 mg/kg/day administered eve2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID416663fAUC in Bacteroides fragilis ATCC 23745 and Enterobacter cloacae isolate 22491-infected BALB/c mouse mixed infection abscesses model at 100 mg/kg administered as single dose2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID584481Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN11 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID26413Half-life is evaluated1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID543955Antibacterial activity against chloramphenicol, tetracycline-resistant Staphylococcus aureus COL-S carrying SAmecA/mecI-mecR1 plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID584479Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN09 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID416826Antimicrobial activity against Bacteroides fragilis ATCC 23745 infected BALB/c mouse mixed infection abscesses model co-infected with Enterobacter cloacae isolate 22491 assessed as reduction in bacterial load per abscess at 384 mg/kg/day administered ever2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID416831Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as increase in resistant bacterial count per abscess at 24 mg/kg/day administ2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID416665Unbound Cmax (fCmax) in Bacteroides fragilis ATCC 23745 and Enterobacter cloacae isolate 22491-infected BALB/c mouse mixed infection abscesses model at 100 mg/kg administered as single dose2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID528525Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B6 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID548256Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID19543Plasma half-life in monkey after intravenous administration1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
AID584469Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP05 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID70419In vitro minimum inhibitory concentration (MIC) against NIHJ JC-2 strain of Escherichia coli1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antibacterial activity of new 1-oxa-1-dethiacephalosporins.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID205388In vitro minimum inhibitory concentration (MIC) against Serratia marcescens.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antibacterial activity of new 1-oxa-1-dethiacephalosporins.
AID584471Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN01 (ATCC 51145T) by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID584293Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP03 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID543954Antibacterial activity against chloramphenicol-resistant Staphylococcus aureus COL carrying mecI-mecR1 plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID584299Antibacterial activity against mecA-negative Staphylococcus fleurettii SFMN01 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID543950Antibacterial activity against oxacillin, chloramphenicol-susceptible and erythromycin, tetracycline-resistant Staphylococcus aureus COL2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID528530Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B40 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID209615In vitro inhibitory activity against Streptococcus pyogenes Park1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID416828Antimicrobial activity against Bacteroides fragilis ATCC 23745 infected BALB/c mouse mixed infection abscesses model co-infected with Enterobacter cloacae isolate 22491 assessed as reduction in bacterial load per abscess at 1536 mg/kg/day administered eve2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID584485Antibacterial activity against mecA-negative Staphylococcus lentus ATCC 29070T by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID543956Antibacterial activity against chloramphenicol, tetracycline-resistant Staphylococcus aureus COL-S carrying SSpbpD/mecI-mecR1 plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID543951Antibacterial activity against oxacillin, chloramphenicol, erythromycin-susceptible and tetracycline-resistant Staphylococcus aureus COL-S with SCCmec excised2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID528522Antimicrobial activity against Streptococcus pneumoniae ATCC 49619 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID528529Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B12 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID528531Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B60 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID584476Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN06 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID528524Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B1 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID528521Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC BAA-611 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID588965Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT32010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID584472Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN02 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID416825Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as bacterial killing at 96 mg/kg/day administered every 4 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID584483Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN13 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID416827Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as reduction in bacterial load per abscess at 384 mg/kg/day administered ever2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID584297Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP07 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID416832Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as increase in resistant bacterial count per abscess at 96 mg/kg/day administ2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID528739Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B516 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID16865Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID416836Antimicrobial activity against Bacteroides fragilis ATCC 23745 infected BALB/c mouse mixed infection abscesses model co-infected with Enterobacter cloacae isolate 22491 assessed as inhibition of emergence of resistance mutation2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID584477Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN07 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID584482Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN12 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID416667fT>MIC in Enterobacter cloacae isolate 22491-infected BALB/c mouse at 100 mg/kg2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID68697In vitro inhibitory activity against Escherichia coli EC141990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID584475Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN05 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID584484Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN14 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID416666Unbound Cmax (fCmax) in Bacteroides fragilis ATCC 23745 and Enterobacter cloacae isolate 22491-infected BALB/c mouse mixed infection abscesses model at 100 mg/kg administered as 36 doses every 2 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID584292Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP02 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID416820Antimicrobial activity against Bacteroides fragilis ATCC 23745 infected BALB/c mouse mixed infection abscesses model co-infected with Enterobacter cloacae isolate 22491 assessed as bacterial killing at 6 mg/kg/day administered every 2 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID416664fAUC in Bacteroides fragilis ATCC 23745 and Enterobacter cloacae isolate 22491-infected BALB/c mouse mixed infection abscesses model at 100 mg/kg administered as 36 doses every 2 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID1219900Activity of recombinant human MRP4 expressed in adenovirus infected HEK293 cell plasma membrane vesicles assessed as transporter-mediated drug uptake after 2 mins by Michaelis-Menten plot analysis in presence of ATP2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID584480Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN10 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID548471Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID416824Antimicrobial activity against Bacteroides fragilis ATCC 23745 infected BALB/c mouse mixed infection abscesses model co-infected with Enterobacter cloacae isolate 22491 assessed as bacterial killing at 96 mg/kg/day administered every 4 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID19544Plasma half-life in rats after intravenous administration1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
AID1820936Binding affinity to Staphylococcus aureus PBP2a measured after 6 hrs by ELISA2022European journal of medicinal chemistry, Feb-05, Volume: 229An unanticipated discovery towards novel naphthalimide corbelled aminothiazoximes as potential anti-MRSA agents and allosteric modulators for PBP2a.
AID528535Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B513 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID584298Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP08 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID584294Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus fleurettii SFMP04 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID40766In vitro minimum inhibitory concentration (MIC) against ATCC 6633 strain of Bacillus subtilis1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antibacterial activity of new 1-oxa-1-dethiacephalosporins.
AID416661Half life in Bacteroides fragilis ATCC 23745 and Enterobacter cloacae isolate 22491-infected BALB/c mouse mixed infection abscesses model at 100 mg/kg administered as single dose2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID416838Ratio of fAUC to MIC in Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 237452007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID528536Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B514 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID548254Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID584468Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP04 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID548257Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID584478Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN08 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID584467Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP03 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID416830Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as increase in resistant bacterial count per abscess at 6 mg/kg/day administe2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID68344In vitro inhibitory activity against Enterobacter cloacae EB51990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID416833Antimicrobial activity against Enterobacter cloacae isolate 22491 infected BALB/c mouse mixed infection abscesses model co-infected with Bacteroides fragilis ATCC 23745 assessed as increase in resistant bacterial count per abscess at 6 mg/kg/day administe2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
AID528523Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC 12403 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID528528Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B10 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID584470Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus vitulinus SVMP06 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID528740Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC BAA-611 harboring PBP-2X Q557E mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID207962In vitro minimum inhibitory concentration (MIC) against 209P JC-1 strain of Staphylococcus aureus1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antibacterial activity of new 1-oxa-1-dethiacephalosporins.
AID584474Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN04 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID584473Antibacterial activity against mecA-negative Staphylococcus vitulinus SVMN03 by agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1803130Esterase Activity Assay from Article 10.3109/14756366.2011.604852: \\Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study.\\2012Journal of enzyme inhibition and medicinal chemistry, Oct, Volume: 27, Issue:5
Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study.
AID1803293Glutathione S-transferase Activity Assay from Article 10.3109/14756366.2012.688042: \\Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
AID1803294Glutathione Peroxidase Activity Assay from Article 10.3109/14756366.2012.688042: \\Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
AID1803292Glutathione Reductase Activity Assay from Article 10.3109/14756366.2012.688042: \\Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.55)18.7374
1990's2 (9.09)18.2507
2000's10 (45.45)29.6817
2010's8 (36.36)24.3611
2020's1 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.00 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index91.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery in Soba Hospital Sudan [NCT01347593]Phase 4220 participants (Actual)Interventional2011-05-31Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance [NCT04771884]300 participants (Anticipated)Observational2020-10-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]